Kaken Pharmaceutical (4521.T) Earnings Analysis
Kaken Pharmaceutical (4521.T) next reports earnings on 2026-08-07. Last quarter (2026-02-06) it missed with EPS 10.71 JPY vs 24.79 JPY est (-56.8%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E 68.41.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4521.T next report earnings?
| Next earnings date | 2026-08-07 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | 19.34B |
4521.T earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-06 | 10.71 JPY | 24.79 JPY | -56.8% | Miss |
| 2025-11-10 | 19.03 JPY | n/a | n/a | n/a |
| 2025-05-12 | -140.89 JPY | n/a | n/a | n/a |
| 2025-02-06 | 129.08 JPY | n/a | n/a | n/a |
| 2024-11-08 | 330.9 JPY | n/a | n/a | n/a |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
4521.T valuation and analyst view
| Trailing P/E | 68.41 |
|---|---|
| Trailing EPS | 56.592 JPY |
| Price / book | 0.99 |
| Dividend yield | 4.91% |
| Market cap | 147.31B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Kaken Pharmaceutical (4521.T)'s next earnings date?
Kaken Pharmaceutical is next scheduled to report on 2026-08-07 and revenue estimate of 19.34B.
Did 4521.T beat earnings last quarter?
In its 2026-02-06 report, 4521.T posted EPS of 10.71 JPY versus a 24.79 JPY estimate — a miss of 56.8%.
What is 4521.T's earnings track record?
Over the last 1 reported quarters with consensus data, 4521.T beat estimates 0 times (0%).
What is 4521.T's current P/E ratio and EPS?
4521.T trades at a trailing P/E of 68.41 on trailing EPS of 56.59231885970701 JPY.
What do analysts rate 4521.T?
4521.T has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.